TickerFacts.

Neuphoria Therapeutics Inc. (NEUP): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$663.0K
Year ended 2026-06-30
0.0%
3-year compound annual growth
$663.2K2023-06-30: $663.2K2024-06-30: $663.0K2025-06-30: $662.9K2026-06-30: $663.0K$663.0K
2023-06-30 Depreciation & Amortization (USD) 2026-06-30
Period endedDepreciation & AmortizationChange YoYSource filing
2026-06-30$663.0K0.0%2026-09-18, From 2025-07-01
2025-06-30$662.9K0.0%2026-09-18, From 2024-07-01
2024-06-30$663.0K0.0%2025-09-29, From 2023-07-01
2023-06-30$663.2Kn/a2024-09-30, From 2022-07-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Neuphoria Therapeutics Inc. (NEUP)2026-06-30$663.0K0.0%
Longeveron Inc. (LGVN)2025-12-31$800.0K+14.3%
China SXT Pharmaceuticals, Inc. (SXTC)2026-03-31$73.7K-10.5%
Vistagen Therapeutics, Inc. (VTGN)2026-03-31$199.0K+32.7%
IGC Pharma, Inc. (IGC)2025-03-31$618.0K-3.0%
Dare Bioscience, Inc. (DARE)2025-12-31$1.63Mn/m
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$43.3K+269.5%
Northwest Biotherapeutics Inc (NWBO)2025-12-31$2.06M+18.3%
Shattuck Labs, Inc. (STTK)2025-12-31$3.70M-2.6%

Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗